GlassScriptPhysician profile
Thomas A Haffey
NPI 1063400166
$7,136.81
in general payments reported to CMS, 2019-2025
37 companies · $1,529 in 2025
The $1,529 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,288 · 2020: $672 · 2021: $661 · 2022: $1,627 · 2023: $1,183 · 2024: $177 · 2025: $1,529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,888.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $652.04 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $497.39 | 2019-2025 | |
| Amarin Pharma, INC. | $470.37 | 2019-2022 | |
| Amgen INC. | $451.71 | 2019-2025 | Repatha |
| Pfizer INC. | $377.50 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $370.41 | 2019-2023 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $370.08 | 2021-2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $341.95 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $308.41 | 2019-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $307.43 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $284.79 | 2019-2023 | |
| Boston Scientific Corporation | $261.23 | 2023-2025 | Watchman Flx, Watchman Access System, Lux-Dx Insertable Cardiac Monitor |
| Merck Sharp & Dohme LLC | $253.26 | 2021-2025 | Verquvo |
| Abbott Laboratories | $237.80 | 2022-2025 | Mitraclip, Triclip, Jot Dx |
| Bayer Healthcare Pharmaceuticals INC. | $225.50 | 2021-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $189.35 | 2022-2025 | Biomonitor, Acticor 7 Vr-T Dx, Renamic Neo |
| Novo Nordisk INC | $186.89 | 2019-2025 | Wegovy, Ozempic |
| Kowa Pharmaceuticals America, INC. | $185.59 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $181.25 | 2019-2025 | Farxiga, Lokelma |
| Medtronic, INC. | $180.25 | 2025 | Closurefast, Linq II, Cobalt Dr Mri Surescan |
| Cvrx, INC. | $175.54 | 2023-2025 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $138.52 | 2022-2023 | Optimizer |
| Baxter Healthcare | $71.72 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Abbvie INC. | $56.34 | 2023 | |
| Genzyme Corporation | $54.19 | 2022 | |
| Edwards Lifesciences Corporation | $50.63 | 2022-2025 | Sapien 3 Ultra Resilia |
| Kestra Medical Technology Services, INC. | $44.89 | 2022-2023 | Assure Wcd |
| Regeneron Healthcare Solutions, INC. | $40.18 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $31.07 | 2019 | |
| Astellas Pharma US INC | $21.79 | 2020 | |
| Heartflow, INC. | $21.45 | 2022 | |
| Lilly USA, LLC | $17.99 | 2025 | Mounjaro |
| Philips North America LLC | $17.62 | 2025 | Event |
| Inspire Medical Systems, INC. | $17.38 | 2023 | Inspire |
| Alnylam Pharmaceuticals INC. | $16.44 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $16.16 | 2023 | Inpefa |
| Medtronic Vascular, INC. | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Haffey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.